CHMP adopted a positive opinion recommending EU approval of Sarclisa (isatuximab) subcutaneous in combination with approved standard-of-care regimens, Sanofi said. This regulatory milestone advances commercialization prospects in Europe and represents a modestly positive catalyst for Sanofi shares pending final European Commission approval.
CHMP adopted a positive opinion recommending EU approval of Sarclisa (isatuximab) subcutaneous in combination with approved standard-of-care regimens, Sanofi said. This regulatory milestone advances commercialization prospects in Europe and represents a modestly positive catalyst for Sanofi shares pending final European Commission approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
